Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novartis Ag (NVS)
NYSE:NVS
Holding NVS?
Track your performance easily
Earnings Data
Report Date
Jan 31, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
1.82Last Year’s EPS
1.53Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 18, 2018
|% Change Since: -14.32%
|Next Earnings Date:Jul 18, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted strong operational performance and strategic FDA approvals, leading to raised guidance. Despite some challenges like currency impacts and program termination, the positive aspects largely outweighed the negatives.Company Guidance
In the Q3 2024 earnings call, Novartis reported robust financial performance, with sales growing by 10% and core operating income increasing by 20% in constant currency, resulting in a core margin of 40.1%. The company highlighted significant achievements, including FDA approvals for Kisqali and Fabhalta, and the acceptance of Pluvicto's filing. Moreover, Novartis raised its 2024 guidance for the third time, now expecting low double-digit sales growth and high teens core operating income growth. The company anticipates no generic entries for Tasigna, Promacta, or Entresto in the U.S. in 2024, and projects mid-2025 for these occurrences. Free cash flow reached $6 billion in the quarter, the highest ever recorded, reflecting strong operational efficiencies.Strong Operational Performance
Sales grew 10%, and core operating income was up 20% in constant currency. The core margin increased to 40.1%.
FDA Approvals and Pipeline Successes
Kisqali received FDA approval and CHMP-positive opinion for new indications. Fabhalta got accelerated approval in IgA nephropathy, with Pluvicto filing accepted for a new population.
Guidance Raise
For the third time this year, Novartis raised its top and bottom line guidance, expecting sales to grow low double digits and core operating income in the high teens.
Free Cash Flow Record
Free cash flow reached $6 billion, the highest ever achieved in a quarter.
Entresto and Cosentyx Growth
Entresto sales increased 26%, and Cosentyx grew 28%, driven by strong performance in new launches and regions.
Kesimpta and Kisqali Sales Surge
Kesimpta sales grew 56% when adjusted for a onetime RD adjustment, and Kisqali saw a 43% growth.
---
NVS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NVS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 29, 2024 | $115.63 | $110.53 | -4.41% |
| Jul 18, 2024 | $111.80 | $107.22 | -4.10% |
| Apr 23, 2024 | $95.12 | $97.28 | +2.27% |
| Jan 31, 2024 | $105.17 | $100.99 | -3.97% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Novartis Ag (NVS) report earnings?
Novartis Ag (NVS) is schdueled to report earning on Jan 31, 2025, TBA Not Confirmed.
What is Novartis Ag (NVS) earnings time?
Novartis Ag (NVS) earnings time is at Jan 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NVS EPS forecast?
NVS EPS forecast for the fiscal quarter 2024 (Q4) is 1.82.
---
